GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that encouraging data from malaria vaccine studies using the company’s adenovector technologies were reported in multiple presentations by scientists representing GenVec and its collaborators at the Malaria Vaccines for the World Conference at the Royal Society of Medicine in London, U.K., September 17-19, 2007.
